Effects of Ghrelin on hypertension and insulin resistance in fructose-fed rats

National Medical Journal of China

Volumn 93, Issue 12, 2013, Pages 935-938

  Zhao, Yin Tao ^a   Shao, Li ^b   Yang, Hai Bo ^a   Li, Ling ^a   Teng, Li Li ^b  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b NONE

Author keywords

Fructose; Ghrelin; Hypertension; Insulin resistance; Rat

Indexed keywords

FRUCTOSE; GHRELIN; GLUCOSE; INSULIN; ISOPROSTANE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID ANALYSIS; MALE; NONHUMAN; RAT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ANIMALS; FRUCTOSE; GHRELIN; HYPERTENSION; INSULIN RESISTANCE; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84876345149     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2013.12.014     Document Type: Article

References (14)

1. Swislocki A L, Hoffman B B, Reaven G M. Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. Am J Hypertens, 1989, 2: 419-423.
2. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 1999, 402:656-660.
3. Tabak O, Gelisgen R, Cicekci H, et al. Circulating levels of adiponectin, orexin-A, ghrelin and the antioxidant paraoxonase-1 in metabolic syndrome. Minerva Med, 2012, 103:323-329.
4. Li Z F, Guo Z F, Yang S G, et al. Circulating ghrelin and ghrelin to obestatin ratio are low in patients with untreated mild-to-moderate hypertension. Regul Pept, 2010, 165:206-209.
5. Gelling R W, Overduin J, Morrison C D, et al. Effect of uncontrolled diabetes on plasma ghrelin concentrations and ghrelin-induced feeding. Endocrinology, 2004, 145: 4575-4582.
6. Rask-Madsen C, Kahn C R. Tissue-specific insulin signaling, metabolic syndrome, and cardiovascular diseas. Arterioscler Thromb Vasc Biol, 2012, 33:2052-2059.
7. 2010, 90:1537-1541.
8. Nagaya N, Uematsu M, Kojima M, et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation, 2001, 104:2034-2038.
9. Nagaya N, Kojima M, Uematsu M, et al. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol, 2001, 2805:R1483-1487.
10. Okumura H, Nagaya N, Enomoto M, et al. Vasodilatory effect of ghrelin, an endogenous peptide from the stomach. J Cardiovasc Pharmacol, 2002, 39: 779-783.
11. Wiley K E, Davenport A P. Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1. Br J Pharmacol, 2002, 136: 1146-1152.
12. Verhulst P J, Depoortere I. Ghrelin's second life: from appetite stimulate to glucose reguator. World J Gastroenterol, 2012, 18: 3183-3195.
13. Gauna C, Meyler F M, Janssen J A, et al. Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity. J Clin Endocrinol Metab, 2004, 89:5035-5042.
14. Tabak O, Gelisgen R, Erman H, et al. Oxidative lipid, protein, and DNA damage as oxidative stress markers in vascular complications of diabetes mellitus. Clin Invest Med, 2011, 34: E163-171.